Provided by Tiger Fintech (Singapore) Pte. Ltd.

Atea Pharmaceuticals, Inc.

2.93
-0.0900-2.98%
Volume:217.57K
Turnover:644.05K
Market Cap:250.59M
PE:-1.47
High:3.04
Open:3.04
Low:2.90
Close:3.02
Loading ...

Company Profile

Company Name:
Atea Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
56
Office Location:
225 Franklin Street,Suite 2100,Boston,Massachusetts,United States
Zip Code:
02110
Fax:
- -
Introduction:
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Directors

Name
Position
Jean Pierre Sommadossi
President and Chief Executive Officer and Chairman of the Board of Director
Andrew Hack
Director
Barbara Duncan
Director
Bruce Polsky
Director
Bruno Lucidi
Director
Franklin Berger
Director
Isaac Cheng
Director
Polly A. Murphy
Director

Shareholders

Name
Position
Jean Pierre Sommadossi
President and Chief Executive Officer and Chairman of the Board of Director
Andrea Corcoran
Chief Financial Officer, Executive Vice President, Legal and Secretary
Wayne Foster
Senior Vice President, Finance and Administration
Janet Hammond
Chief Development Officer
John Vavricka
Chief Commercial Officer
Maria Arantxa Horga
Acting Chief Medical Officer